DynaGen, Alpharma deal

DYGN completed its purchase of the tablet business of Alpharma's Able Laboratories Inc. unit, a generic pharmaceutical products subsidiary, for $550,000 (see BioCentury Aug. 19.). DYGN is creating a ...